Skip to main content

Table 3 Mean of responding and non-responding lesions, where a reduction in TLG of at least 50% was chosen to represent a significant metabolic response

From: Individualised dosimetry and safety of SIRT for intrahepatic cholangiocarcinoma

Parameter Mean value p value
Significant response Non-significant response
Baseline TLGa 932 ± 1522 2152 ± 2302 0.101
Baseline SUVmaxb 11.4 ± 3.8 12.3 ± 5.1 0.336
Baseline volume (cc) 182 ± 264 333 ± 346 0.162
Davgc 74 ± 32 61 ± 38 0.299
D70d 42 ± 16 37 ± 31 0.617
V50e 54 ± 26 48 ± 30 0.548
BED 85 ± 44 75 ± 56 0.604
EUD 49 ± 16 39 ± 22 0.146
CoVdosef 0.542 ± 0.198 0.758 ± 0.356 0.030
CoVSUVg 0.274 ± 0.103 0.266 ± 0.069 0.806
  1. aTotal lesion glycolysis
  2. bStandardised uptake value (maximum)
  3. cAverage dose
  4. dMinimum dose to 70% of volume
  5. eVolume receiving at least 50 Gy
  6. fCoefficient of variation of absorbed dose
  7. gCoefficient of variation of SUV